INTERLEUKIN-2 INDUCES CD8(-CELL-MEDIATED SUPPRESSION OF HUMAN-IMMUNODEFICIENCY-VIRUS REPLICATION IN CD4(+) T-CELLS AND THIS EFFECT OVERRIDES ITS ABILITY TO STIMULATE VIRUS EXPRESSION() T)

Citation
Al. Kinter et al., INTERLEUKIN-2 INDUCES CD8(-CELL-MEDIATED SUPPRESSION OF HUMAN-IMMUNODEFICIENCY-VIRUS REPLICATION IN CD4(+) T-CELLS AND THIS EFFECT OVERRIDES ITS ABILITY TO STIMULATE VIRUS EXPRESSION() T), Proceedings of the National Academy of Sciences of the United Statesof America, 92(24), 1995, pp. 10985-10989
Citations number
23
Categorie Soggetti
Multidisciplinary Sciences
ISSN journal
00278424
Volume
92
Issue
24
Year of publication
1995
Pages
10985 - 10989
Database
ISI
SICI code
0027-8424(1995)92:24<10985:IICSOH>2.0.ZU;2-0
Abstract
The nonlytic suppression of human immunodeficiency virus (HIV) product ion from infected CD4(+) T cells by CD8(+) lymphocytes from HIV-infect ed individuals is one of the most potent host-mediated antiviral activ ities observed in vitro. We demonstrate that the pleiotropic cytokine interleukin 2 (IL-2), but not IL-12, is a potent inducer of the CD8(+) HIV suppressor phenomenon. IL-2 induces HIV expression in peripheral blood or lymph node mononuclear cells from HIV-infected individuals in the absence of CD8(+) T cells. However, IL-2 induces CD8(+) T cells t o suppress HIV expression when added back to these cultures, and this effect dramatically supersedes the ability of IL-2 to induce HIV expre ssion. Five to 25 times fewer CD8(+) cells were required to obtain com parable levels of inhibition of viral production if they were activate d in the presence of IL-2 as compared with IL-12 or no exogenous cytok ine. Furthermore, IL-2 appeared either to induce a qualitative increas e in HIV suppressor cell activity or to increase the relative frequenc y of suppressor cells in the activated (CD25(+)) CD8(+) populations. A nalyses of proviral levels in peripheral blood mononuclear cells sugge st that CD8(+) T cell-mediated lysis of in vivo infected cells is not induced by IL-2. These results have implications for our understanding of the effects of impaired IL-2 production during HIV disease as well as the overall effects of IL-2-based immunotherapy on HIV replication in vivo.